Sec Form 4 Filing - Kirby Daniel Gordon @ IOVANCE BIOTHERAPEUTICS, INC. - 2025-02-10

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Kirby Daniel Gordon 2. Issuer Name and Ticker or Trading Symbol IOVANCE BIOTHERAPEUTICS, INC. [ IOVA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Commercial Officer (Last) (First) (Middle) C/O IOVANCE BIOTHERAPEUTICS, INC., 825 INDUSTRIAL ROAD, SUITE 100 3. Date of Earliest Transaction (MM/DD/YY) 02/10/2025 (Street) SAN CARLOS, CA94070 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Options (Right to Buy) $ 5.32 02/10/2025 A 35,000 ( 1 ) 02/10/2035 Common stock 35,000 $ 0 35,000 D Restricted Stock Units ( 2 ) 02/10/2025 A 120,000 ( 1 ) ( 1 ) Common stock 120,000 $ 0 120,000 D Performance Stock Units ( 3 ) 02/10/2025 A 150,000 ( 4 ) ( 5 ) ( 5 ) Common stock 150,000 $ 0 150,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Kirby Daniel Gordon C/O IOVANCE BIOTHERAPEUTICS, INC. 825 INDUSTRIAL ROAD, SUITE 100 SAN CARLOS, CA94070 Chief Commercial Officer Signatures /s/ Daniel Gordon Kirby 02/12/2025 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units ("RSUs") and options are each exercisable as follows: (i) RSUs and options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining RSUs and options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. ( 2 )Each RSU represents a contingent right to receive one share of the Issuer's common stock. ( 3 )Each performance stock unit ("PSU") converts into one share of the Issuer's common stock. ( 4 )Up to 150,000 shares of the Issuer's common stock underlying the PSUs may be earned subject to achievement of certain financial milestones. ( 5 )Such earned PSUs shall vest on the date that the Issuer publicly announces its 2025 financial results by filing its Form 10-K with the U.S. Securities and Exchange Commission.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.